2 citations
,
October 2025 in “Discover Immunity.” This review discusses the classification, diagnosis, and potential treatment pathways for Alopecia Areata, emphasizing the complex genetic and immunological factors involved, but reports no new clinical results.
3 citations
,
June 2025 in “Biomedicines” This review discusses the potential link between gut microbiota alterations and the onset and progression of alopecia areata, identifying it as a possible pathogenetic factor and therapeutic target, but reports no new clinical results.
6 citations
,
January 2024 in “Journal of Cosmetic Dermatology” Alopecia areata patients have worse quality of life, anxiety, and depression than vitiligo patients.
91 citations
,
May 2023 in “Journal of Cutaneous Medicine and Surgery” Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.
4 citations
,
October 2022 in “Genes” This review discusses the role of cutaneous and intestinal microbiota in the development of alopecia areata, summarizing current literature without reporting new clinical results.
40 citations
,
August 2022 in “Frontiers in immunology” This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.
13 citations
,
January 2022 in “Advances in Dermatology and Allergology” This review discusses the relationship between gut microbiota and alopecia areata, and it does not report new clinical results.
55 citations
,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This review discusses emerging research areas in alopecia areata pathobiology, highlighting the potential roles of unconventional immune cells and the need for more targeted therapeutic strategies, but reports no new experimental results.
73 citations
,
April 2019 in “Experimental Dermatology” This review explores the hair follicle microbiome's interaction with the immune system, discussing its potential clinical implications for scalp health and disease but reports no new clinical results.
64 citations
,
July 2016 in “Journal of Immunology” In this study, blocking the CXCR3 receptor in mice prevented the development of alopecia areata by inhibiting the accumulation of specific T cells in the skin, suggesting a potential therapeutic approach for humans.
144 citations
,
July 2015 in “Clinical, Cosmetic and Investigational Dermatology” This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.